News

Filter

Current filters:

Immunologicals

1 to 9 of 269 results

UCB's full-year results

UCB's full-year results "confirm position of strength"

27-02-2015

The 2014 full-year financial results from Belgian drugmaker UCB “confirmed the position of strength”…

BelgiumCimziaFinancialImmunologicalsKeppraNeuproNeurologicalPharmaceuticalUCBVimpat

AstraZeneca inks deal with Orca for autoimmune disease drugs

AstraZeneca inks deal with Orca for autoimmune disease drugs

25-02-2015

Anglo-Swedish pharma major AstraZeneca and Orca Pharmaceuticals, a UK based biopharmaceutical company,…

AstraZenecaBiotechnologyImmunologicalsInflammatory diseasesLicensingOrca PharmaceuticalsRespiratory and PulmonaryUK

Intas becomes first Indian company to launch biosimilar in the EU

Intas becomes first Indian company to launch biosimilar in the EU

23-02-2015

Indian biopharma company Intas has become the first Indian company to launch a biosimilar in highly regulated…

BiosimilarsBiotechnologyFilgrastimHematologyImmunologicalsIndiaIntas PharmaceuticalsMarkets & MarketingRegulation

Genmab inks DuoBody deal with BioNovion in the field of immuno-oncology

19-02-2015

Danish biotech company Genmab has entered into a co-development and commercialization agreement with…

BioNovionBiotechnologyDuoBodyGenmabImmunologicalsLicensingOncologyResearch

Immune Pharmaceuticals appoints Paul Nadler as acting executive VP of R&D and CMO

Immune Pharmaceuticals appoints Paul Nadler as acting executive VP of R&D and CMO

09-02-2015

Israel-based Immune Pharmaceuticals has appointed Paul Nadler as acting executive vice president of research…

BoardroomImmune PharmaceuticalsImmunologicalsIsraelPharmaceutical

Biomay announces positive Phase IIb study of BM32 grass pollen vaccine

Biomay announces positive Phase IIb study of BM32 grass pollen vaccine

28-01-2015

Vienna-based allergy immunotherapy specialist Biomay has successfully completed a Phase IIb study of…

BiomayBM32ImmunologicalsPharmaceuticalResearchSwitzerland

ALK's partner Torii submits NDA in Japan for house dust mite sublingual tablet

ALK's partner Torii submits NDA in Japan for house dust mite sublingual tablet

26-01-2015

Denmark-based allergy specialist ALK Abello’s Japanese partner, Torii Pharmaceutical, has submitted…

ALK AbelloImmunologicalsJapanPharmaceuticalRegulationSLIT-tabletTorii Pharma

Seth Elliott appointed president and chief operating officer of Immune Therapeutics

14-01-2015

Immunotherapy specialist Immune Therapeutics has appointed Seth Elliott as president and chief operating…

BiotechnologyBoardroomImmune TherapeuticsImmunologicalsUSA

1 to 9 of 269 results

COMPANY SPOTLIGHT

Menarini

Back to top